AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.4 |
Market Cap | 167.06M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.09 |
PE Ratio (ttm) | -16.11 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.55 |
Volume | 2,108,460 |
Avg. Volume (20D) | 5,060,686 |
Open | 1.47 |
Previous Close | 1.47 |
Day's Range | 1.45 - 1.60 |
52-Week Range | 0.66 - 2.97 |
Beta | undefined |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
Analyst Forecast
According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 382.76% from the latest price.
Next Earnings Release
Analysts project revenue of $43.88M, reflecting a -52.06% YoY shrinking and earnings per share of -0.18, making a -70.97% decrease YoY.
1 month ago · seekingalpha.com
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing DevelopmentCoherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS hol...